bb 21217

Drug Profile

bb 21217

Alternative Names: Anti-BCMA CAR T-cell- bluebird bio/Celgene; bb21217

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator bluebird bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies
  • Mechanism of Action B-cell maturation antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 05 Oct 2017 bb 21217 receives Orphan Drug status for Multiple myeloma in USA
  • 28 Sep 2017 bb 21217 licensed to Celgene Corporation worldwide
  • 16 Aug 2017 Phase-I clinical trials in Multiple myeloma (Refractory metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT03274219)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top